Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. (Q51293370)

2 April 2018

title

Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. (English)

1 reference

2 April 2018

author name string

Michael A Weber

1

1 reference

2 April 2018

Traci A Mansfield

2

1 reference

2 April 2018

Federica Alessi

3

1 reference

2 April 2018

Nayyar Iqbal

4

1 reference

2 April 2018

Shamik Parikh

5

1 reference

2 April 2018

Agata Ptaszynska

6

1 reference

2 April 2018

publication date

1 December 2015

1 reference

2 April 2018

published in

Blood Pressure

1 reference

2 April 2018

volume

25

1 reference

2 April 2018

page(s)

93-103

1 reference

2 April 2018

issue

2

1 reference

2 April 2018

Standards of medical care in diabetes--2014

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Associati

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Blood pressure levels and stroke: J-curve phenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08037051.2015.1116258

10.3109/08037051.2015.1116258

21 January 2018

Identifiers

DOI

1 reference

2 April 2018

PubMed ID

26623980

1 reference

2 April 2018